Year: 2011
Type: article
Study designs: Systematic Review, Meta-Analysis
Abstract: Objectives To compare the adverse effects of therapy with tumour necrosis factor blocker -etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), golimumab (Simponi) and certolizumab (Cimzia) -interleukin (IL)-1 antagonist -anakinra (Kineret) -IL-6 antagonist -tocilizumab (RoActemra) -anti-CD28 -abatacept (Orencia) -and anti-B cell -rituximab (MabThera)in patients with any disease condition except human immunodeficiency disease (HIV/AIDS).
Source: Prescriber
DOI: 10.1002/psb.747
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4253822685
